A randomized, phase II/III study of pegylated-liposomal-doxorubicin and atezolizumab (IND #134427) versus pegylated-liposomal-doxorubicin, bevacizumab and atezolizumab versus pegylated-liposomal-doxorubicin and bevacizumab in platinum-resistant ovarian cancer (NRG-GY009)

被引：0

作者：

O'Cearbhaill, Roisin ^{[1
]}

Sill, Michael ^{[2
]}

Duong, Hoa ^{[3
]}

Waggoner, Steven ^{[4
]}

Grisham, Rachel ^{[1
]}

Backes, Floor ^{[5
]}

Mannel, Robert ^{[6
]}

Tanyi, Janos ^{[7
]}

Powell, Matthew ^{[8
]}

Mathews, Cara ^{[9
]}

Ghamande, Sharad ^{[10
]}

Mcnally, Leah ^{[11
]}

Olawaiye, Alexander ^{[12
]}

Bender, David ^{[13
]}

Duska, Linda ^{[14
]}

Lankes, Heather ^{[15
]}

Zamarin, Dmitriy ^{[16
]}

Schilder, Russell ^{[17
]}

Bookman, Michael ^{[18
]}

Aghajanian, Carol ^{[1
]}

机构：

[1] Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, Med, New York, NY USA

[2] NRG Oncol Stat & Data Management Ctr, Biostat & Bioinformat Dept, Buffalo, NY USA

[3] Kaiser Permanente Sacramento, Hematol Oncol, Sacramento, CA USA

[4] CWRU Case Comprehens Canc Ctr, Gynecol Oncol, Cleveland, OH USA

[5] Ohio State Univ, Comprehens Canc Ctr, Gynecol Oncol, Columbus, OH USA

[6] Univ Oklahoma, Hlth Sci Ctr, Obstet & Gynecol, Oklahoma City, OK USA

[7] Univ Penn, Abramson Canc Ctr, Obstet & Gynecol, Philadelphia, PA 19104 USA

[8] Washington Univ, Gynecol Oncol, St Louis, MO 63110 USA

[9] Women & Infants Hosp Rhode Isl, Obstet & Gynecol, Providence, RI USA

[10] Georgia Cares Minor Underserved NCORP, Gynecol Oncol, Augusta, GA USA

[11] Duke Canc Inst, Gynecol Oncol, Durham, NC USA

[12] UPMC Hillman Canc Ctr, Gynecol Oncol, Pittsburgh, PA USA

[13] Univ Iowa, Obstet & Gynecol, Iowa City, IA USA

[14] Univ Virginia, Gynecol Oncol, Canc Ctr, Charlottesville, VA USA

[15] NRG Oncol Biospecimen Bank Columbus, Translat Sci Operat, Columbus, OH USA

[16] Icahn Sch Med Mt Sinai, Hematol Oncol, New York, NY 10029 USA

[17] Thomas Jefferson Univ, Gynecol Med Oncol, Philadelphia, PA 19107 USA

[18] Kaiser Permanente Northern Calif, Gynecol Oncol, San Francisco, CA USA

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2023年 / 33卷 / SUPPL_4期

关键词：

D O I：

10.1136/ijgc-2023-IGCS.5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PO005LBA

引用

页码：A4 / A4

页数：1

共 50 条

[41] PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer
Naumann, R. W.
Coleman, R. L.
Burger, R. A.
Herzog, T. J.
Morris, R.
Sausville, E. A.
Kutarska, E.
Ghamande, S. A.
Gabrail, N. Y.
De Pasquale, S.
Nowara, E.
Gilbert, L.
Caton, J. R.
Gersh, R. H.
Teneriello, M. G.
Harb, W. A.
Konstantinopoulos, P.
Symanowski, J. T.
Lovejoy, C.
Messmann, R. A.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[42] PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer
Naumann, R. W.
Symanowski, J. T.
Ghamande, S. A.
Gabrail, N. Y.
Gilbert, L.
Teneriello, M. G.
Sutton, G.
Lovejoy, C.
Messmann, R. A.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
[43] A phase I/II study of maplirpacept in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum-resistant ovarian cancer (OC): Phase 1 results
Street, Daron G.
Kuttschreuter, Luke
Starks, David
Mahdi, Haider
Linn, Carlos
Pavlov, Dmitri
Peguero, Julio Antonio
Chawla, Sant P.
Bruns, Ingmar
Waggoner, Steven E.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[44] A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK
Smith, DH
Adams, JR
Johnston, SRD
Gordon, A
Drummond, MF
Bennett, CL
ANNALS OF ONCOLOGY, 2002, 13 (10) : 1590 - 1597
[45] Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer
John J Kavanagh
Charles F Levenback
Pedro T Ramirez
Judith L Wolf
Carla L Moore
Marsha R Jones
Lisa Meng
Gail L Brown
Robert C Bast
Journal of Hematology & Oncology, 3
[46] Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer
Kavanagh, John J.
Levenback, Charles F.
Ramirez, Pedro T.
Wolf, Judith L.
Moore, Carla L.
Jones, Marsha R.
Meng, Lisa
Brown, Gail L.
Bast, Robert C., Jr.
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2010, 3
[47] Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer
Ferrandina, Gabriella
Ludovisi, Manuela
Lorusso, Domenica
Pignata, Sandro
Breda, Enrico
Savarese, Antonella
Del Medico, Pietro
Scaltriti, Laura
Katsaros, Dionyssios
Priolo, Domenico
Scambia, Giovanni
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (06) : 890 - 896
[48] Phase II Study of Bortezomib and Pegylated Liposomal Doxorubicin in the Treatment of Metastatic Breast Cancer
Irvin, William J., Jr.
Orlowski, Robert Z.
Chiu, Wing-Keung
Carey, Lisa A.
Collichio, Frances A.
Bernard, Philip S.
Stijleman, Inge J.
Perou, Charles
Ivanova, Anastasia
Dees, E. Claire
CLINICAL BREAST CANCER, 2010, 10 (06) : 465 - 470
[49] A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer
Faruk Tas
Nese Guney
Duygu Derin
Adnan Aydiner
Erkan Topuz
International Journal of Clinical Oncology, 2008, 13 : 156 - 160
[50] THE ROLE OF PEGYLATED LIPOSOMAL DOXORUBICIN AND WEEKLY PACLITAXEL WITH OR WITHOUT BEVACIZUMAB IN PROLONGING THE PLATINUM-FREE INTERVAL IN EPITHELIAL OVARIAN CANCER
El-Modir, Ahmed
Doyle, Yvonne
Fernando, Indrajit
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A317 - A317

← 1 2 3 4 5 →